Pfizer: 2026 Feels Like Another Lost Year After Yesterday's Guidance Update
Summarize this article with:
Edmund InghamInvesting Group LeaderFollow5ShareSavePlay(19min)Comment(1)SummaryPfizer Inc. provided early 2025 and 2026 guidance, projecting flat-to-declining revenues and EPS, highlighting persistent growth and profitability challenges.PFE faces major patent expiries, declining COVID franchise revenues, and high debt, all weighing on near-term growth prospects and valuation.The Metsera obesity drug acquisition offers a potential 2026 catalyst, but efficacy and competitive differentiation remain unproven and high risk.Despite a sector-leading 6.75% dividend yield, management signals capital allocation will prioritize business reinvestment over near-term dividend growth. JHVEPhoto/iStock Editorial via Getty Images Investment Overview Yesterday, the Pharma giant Pfizer Inc. (PFE) took the unusual step of not only providing its full-year 2025 revenue and earnings numbers, but also providing precise guidance for full-year 2026. Usually, companies shareThis article was written byEdmund Ingham14.45K FollowersFollowEdmund Ingham is a biotech consultant. He has been covering biotech, healthcare, and pharma for over 5 years, and has put together detailed reports of over 1,000 companies. He leads the investing group Haggerston BioHealth. The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts for all the Big Pharmas, forecasting, integrated financial statements, discounted cash flow analysis and market by market analysis. Learn more.Analyst’s Disclosure:I/we have a beneficial long position in the shares of PFE either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.